Glp-1 agonists and weight loss
We used random effects models for the primary meta-analyses. We recommend upgrading to the latest version of. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Please note that the JCI no longer supports your version of Internet Explorer. See the related Commentary beginning on page 4223. In order to avoid on- or off-target CNS side effects, it would seem desirable that new drugs for the treatment of obesity specifically target those neurons. Most drugs that have been available to treat obesity are small molecules that cross the blood-brain barrier (BBB) and affect different neuronal networks. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. In the overall analysis, GLP-1R agonists had beneficial effects on systolic and diastolic blood pressure, plasma concentrations of cholesterol, and glycaemic control, but did not have a significant effect on plasma concentrations of liver enzymes. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. GLP-1R agonists were associated with nausea, diarrhoea, and vomiting, but not with hypoglycaemia. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. During the past two decades the physiology and pharmacology of GLP-1 and GLP-1 analogs in glucose, food intake, and body weight control have been gradually dissected ( 12, 13 ). Besides lowering blood glucose, liraglutide also reduces body weight.
1 The World Health Organization estimates that 1. Results 25 trials were included in the analysis. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. 5 billion adults worldwide are overweight and 500 million are obese. Control interventions assessed were placebo, oral antidiabetic drugs, or insulin. Data sources Electronic searches (Cochrane Library, Medline, Embase, and Web of Science) and manual searches (up to May 2011). New agents being considered for the treatment of obesity are analogs of the peripheral peptide hormones, like glucagon-like peptide-1 (GLP-1), peptide YY, and glucagon, and some are antagonists for receptors, like the ghrelin receptor ( 2, 3 ). Conclusions The present review provides evidence that treatment with GLP-1R agonists leads to weight loss in overweight or obese patients with or without type 2 diabetes mellitus. An estimated 44% of the burden for diabetes has been attributed to these weight problems, as well as 23% and 7-41% of the burdens for ischaemic heart disease and specific cancers, respectively. This proportion is smaller in Europe, but continues to increase. Several of those compounds have a rather broad spectrum of effects in the brain, sometimes leading to CNS side effects ( 1 ). Abstract Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. We also did subgroup, sensitivity, regression, and sequential analyses to evaluate sources of intertrial heterogeneity, bias, and the robustness of results after adjusting for multiple testing and random errors. Both peripheral and brain GLP-1 receptors (GLP-1Rs) seem to be involved in mediating the specific effects ( 4 ). We found evidence of intertrial heterogeneity, but no evidence of bias or small study effects in regression analyses. The physiology and pharmacology of GLP-1 are somewhat different. By continuing to browse the site you are agreeing to our use of cookies.
Glp-1 agonists and weight loss video:
glp-1 agonists and weight loss tags:
glp 1 structure agonist weight loss
